xRead - September 2022

Wise et al.

Page 384

Author Manuscript Author Manuscript Author Manuscript Author Manuscript

Study Year LOE Study design Study groups Clinical endpoint Conclusion Philip et al. 1344 2002 1b RCT 1 Montelukast; 2 Loratadine; 3 Placebo Symptoms, QOL, peripheral eosinophil count Montelukast was more effective than placebo in reducing symptoms and peripheral eosinophil count, and improving QOL. Montelukast not directly compared to loratadine. Pullerits et al. 1346 1999 1b RCT 1 Zafirlukast; 2 Beclomethasone; 3 Placebo Symptoms, tissue eosinophilia

Zafirlukast was not different from placebo in symptom or tissue eosinophilia reduction. Both were inferior to intranasal beclomethasone.

INCS = intranasal corticosteroids; LOE = level of evidence; LTRA = leukotriene receptor antagonist; QOL = quality of life; RCT = randomized controlled trial; SLIT = sublingual immunotherapy; SR = systematic review.

Int Forum Allergy Rhinol . Author manuscript; available in PMC 2020 June 10.